S&P 500   4,532.52 (-0.97%)
DOW   34,499.92 (-0.40%)
QQQ   381.68 (-2.11%)
AAPL   162.70 (-0.65%)
MSFT   321.37 (-2.46%)
FB   305.24 (-1.66%)
GOOGL   2,808.22 (-1.79%)
AMZN   3,376.08 (-1.78%)
TSLA   1,030.11 (-5.02%)
NVDA   304.23 (-5.30%)
BABA   113.75 (-6.76%)
NIO   33.52 (-7.40%)
CGC   10.00 (-3.47%)
AMD   142.39 (-5.50%)
GE   92.85 (-2.50%)
MU   82.33 (-0.66%)
T   23.24 (+0.82%)
F   19.36 (-2.57%)
DIS   146.14 (-0.72%)
PFE   53.49 (+0.85%)
AMC   27.66 (-8.65%)
ACB   5.91 (-3.75%)
BA   197.22 (-2.55%)
S&P 500   4,532.52 (-0.97%)
DOW   34,499.92 (-0.40%)
QQQ   381.68 (-2.11%)
AAPL   162.70 (-0.65%)
MSFT   321.37 (-2.46%)
FB   305.24 (-1.66%)
GOOGL   2,808.22 (-1.79%)
AMZN   3,376.08 (-1.78%)
TSLA   1,030.11 (-5.02%)
NVDA   304.23 (-5.30%)
BABA   113.75 (-6.76%)
NIO   33.52 (-7.40%)
CGC   10.00 (-3.47%)
AMD   142.39 (-5.50%)
GE   92.85 (-2.50%)
MU   82.33 (-0.66%)
T   23.24 (+0.82%)
F   19.36 (-2.57%)
DIS   146.14 (-0.72%)
PFE   53.49 (+0.85%)
AMC   27.66 (-8.65%)
ACB   5.91 (-3.75%)
BA   197.22 (-2.55%)
S&P 500   4,532.52 (-0.97%)
DOW   34,499.92 (-0.40%)
QQQ   381.68 (-2.11%)
AAPL   162.70 (-0.65%)
MSFT   321.37 (-2.46%)
FB   305.24 (-1.66%)
GOOGL   2,808.22 (-1.79%)
AMZN   3,376.08 (-1.78%)
TSLA   1,030.11 (-5.02%)
NVDA   304.23 (-5.30%)
BABA   113.75 (-6.76%)
NIO   33.52 (-7.40%)
CGC   10.00 (-3.47%)
AMD   142.39 (-5.50%)
GE   92.85 (-2.50%)
MU   82.33 (-0.66%)
T   23.24 (+0.82%)
F   19.36 (-2.57%)
DIS   146.14 (-0.72%)
PFE   53.49 (+0.85%)
AMC   27.66 (-8.65%)
ACB   5.91 (-3.75%)
BA   197.22 (-2.55%)
S&P 500   4,532.52 (-0.97%)
DOW   34,499.92 (-0.40%)
QQQ   381.68 (-2.11%)
AAPL   162.70 (-0.65%)
MSFT   321.37 (-2.46%)
FB   305.24 (-1.66%)
GOOGL   2,808.22 (-1.79%)
AMZN   3,376.08 (-1.78%)
TSLA   1,030.11 (-5.02%)
NVDA   304.23 (-5.30%)
BABA   113.75 (-6.76%)
NIO   33.52 (-7.40%)
CGC   10.00 (-3.47%)
AMD   142.39 (-5.50%)
GE   92.85 (-2.50%)
MU   82.33 (-0.66%)
T   23.24 (+0.82%)
F   19.36 (-2.57%)
DIS   146.14 (-0.72%)
PFE   53.49 (+0.85%)
AMC   27.66 (-8.65%)
ACB   5.91 (-3.75%)
BA   197.22 (-2.55%)
NASDAQ:MITO

Stealth BioTherapeutics Earnings Date, Estimates, & History

$0.74
-0.10 (-11.73%)
(As of 12/3/2021 10:38 AM ET)
Add
Compare
Today's Range
$0.74
$0.83
50-Day Range
$0.81
$1.48
52-Week Range
$0.72
$2.58
Volume
203 shs
Average Volume
1.71 million shs
Market Capitalization
$42.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.74

Earnings Summary

Upcoming
Earnings Date
Apr. 5
Estimated

Actual EPS
(Nov. 11)
-$0.02

Consensus EPS
(Nov. 11)
-$0.02

Last Year's Q4 EPS
(11/5/2020)
-$0.02

Skip Charts & View Estimated and Actual Earnings Data

Stealth BioTherapeutics Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Stealth BioTherapeutics Estimated Revenue and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Stealth BioTherapeutics (NASDAQ:MITO) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.06 EPS
Next Year EPS Consensus Estimate: $-0.06 EPS

MITO Earnings Information

Stealth BioTherapeutics last posted its earnings data on November 11th, 2021. The reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.02). Stealth BioTherapeutics has generated ($0.41) earnings per share over the last year (($0.41) diluted earnings per share). Earnings for Stealth BioTherapeutics are expected to remain at ($0.06) per share in the coming year. Stealth BioTherapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, April 5th, 2022 based off prior year's report dates.

Stealth BioTherapeutics (NASDAQ:MITO) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueActions
4/5/2022
(Estimated)
        
11/11/2021Q3 2021($0.02)($0.02)($0.03)    
8/5/20216/30/2021($0.02)($0.03)($0.01)($0.03)  
5/18/2021Q1($0.02)($0.01)+$0.01($0.01)  
4/5/202112/31/2020$0.01($0.03)($0.04)($0.36)  
11/5/20209/30/2020($0.02)($0.02)($0.02)  
8/6/20206/30/2020($0.02)($0.02)($0.02)  
5/7/20203/31/2020($0.03)($0.04)($0.01)($0.04)  
4/1/2020Q4 2019($0.04)$0.12+$0.16$0.12$21.09 million
11/14/2019Q3($0.04)($0.04)($0.04)  
8/14/2019Q2($0.0780)($0.04)+$0.0380($0.04)
5/15/2019Q1 2019($0.26)($0.12)+$0.14($0.04)
(Earnings results data provided by Zacks Investment Research)












Stealth BioTherapeutics (NASDAQ:MITO) Earnings Frequently Asked Questions

When is Stealth BioTherapeutics's earnings date?

Stealth BioTherapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, April 5th, 2022 based off last year's report dates. Learn more on MITO's earnings history

Did Stealth BioTherapeutics beat their earnings estimates last quarter?

In the previous quarter, Stealth BioTherapeutics (NASDAQ:MITO) reported ($0.02) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.02). Learn more on MITO's earnings details

How can I listen to Stealth BioTherapeutics's earnings conference call?

The conference call for Stealth BioTherapeutics's latest earnings report can be listened to online. Listen to Conference Call

How can I read Stealth BioTherapeutics's conference call transcript?

The conference call transcript for Stealth BioTherapeutics's latest earnings report can be read online. Read Transcript

How much revenue does Stealth BioTherapeutics generate each year?

Stealth BioTherapeutics (NASDAQ:MITO) has a recorded annual revenue of $21.09 million.

How much profit does Stealth BioTherapeutics generate each year?

Stealth BioTherapeutics (NASDAQ:MITO) has a recorded net income of -$57.46 million. MITO has generated -$0.41 earnings per share over the last four quarters.

What is Stealth BioTherapeutics's EPS forecast for next year?

Stealth BioTherapeutics's earnings are expected to stay at ($0.06) per share in the next year.

This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.